Austin Health

Title
Thoracic Society of Australia and New Zealand clinical practice guideline on adult home oxygen therapy.
Publication Date
2024-09
Author(s)
McDonald, Christine F
Serginson, John
AlShareef, Saad
Buchan, Catherine
Davies, Huw
Miller, Belinda R
Munsif, Maitri
Smallwood, Natasha
Troy, Lauren
Khor, Yet Hong
Subject
clinical respiratory medicine
hypoxaemia
long‐term oxygen therapy
oxygen guideline
oxygen therapy
Type of document
Journal Article
OrcId
0000-0001-6481-3391
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0002-3403-3586
0000-0002-7426-336X
0000-0002-5434-9342
DOI
10.1111/resp.14793
Abstract
This Thoracic Society of Australia and New Zealand Guideline on the provision of home oxygen therapy in adults updates a previous Guideline from 2015. The Guideline is based upon a systematic review and meta-analysis of literature to September 2022 and the strength of recommendations is based on GRADE methodology. Long-term oxygen therapy (LTOT) is recommended for its mortality benefit for patients with COPD and other chronic respiratory diseases who have consistent evidence of significant hypoxaemia at rest (PaO2 ≤ 55 mm Hg or PaO2 ≤59 mm Hg in the presence of hypoxaemic sequalae) while in a stable state. Evidence does not support the use of LTOT for patients with COPD who have moderate hypoxaemia or isolated nocturnal hypoxaemia. In the absence of hypoxaemia, there is no evidence that oxygen provides greater palliation of breathlessness than air. Evidence does not support the use of supplemental oxygen therapy during pulmonary rehabilitation in those with COPD and exertional desaturation but normal resting arterial blood gases. Both positive and negative effects of LTOT have been described, including on quality of life. Education about how and when to use oxygen therapy in order to maximize its benefits, including the use of different delivery devices, expectations and limitations of therapy and information about hazards and risks associated with its use are key when embarking upon this treatment.
Link
Citation
Respirology (Carlton, Vic.) 2024-09; 29(9)
Jornal Title
Respirology (Carlton, Vic.)
ISSN
1440-1843

Files:

NameSizeformatDescriptionLink